

# **CHI-MYST SYNERGY TOPICAL- chitosan ketorolac bupivacaine lidocaine suspension spray, metered**

**Prescription Care LLC**

*Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, [click here](#).*

## **Chi-Myst Synergy Topical**

### **Drug Information**

#### **Warnings and Precautions**

For EXTERNAL use only. AVOID eye contact.

Discontinue Chi-Myst and consult with your physician:

- If your condition worsens
- If your symptoms do not improve after 10 days, unless directed by a physician
- If a rash appears, or reaction to the medication is experienced at the point of application

Chi-Myst includes a chitin derivative, which is produced from shrimp shells. While it is unlikely to affect those suffering from shrimp or shellfish allergies, patients with allergies to shrimp or other shellfish should ask their physician before using Chi-Myst.

#### **Indications/Uses:**

Anti-inflammatory (osteoarthritis, tendonitis, joint or musculoskeletal pain)

#### **How To Take This Medication:**

Adults and children 2 years of age or older SPRAY onto affected area or spray into palm and lightly apply to tender area. Dosage is determined by your physician, and will vary by intensity of pain, as well as the nature, size and location of the affected area. Chi-Myst may be used as often as once every three hours to combat fierce pain and inflammation, or more often if prescribed by your doctor. Use only as directed. Only use the prescribed number of sprays per application, as multiple sprays have not been shown to be any more effective than one or two sprays to the affected area. Most patients prefer to spray Chi-Myst directly on the affected area. It is not recommended to rub-in Chi-Myst, as the transdermal agent absorbs efficiently and naturally through the skin. For particularly tender or isolated areas, and open wounds, it is recommended to spray Chi-Myst on clean fingertips, and gently distribute the medication to the affected area. Allow Chi-Myst to absorb before allowing the treated area to come in contact with clothing or furniture.

#### **Side Effects:**

Due to the unique transdermal delivery method of the active ingredients, no side effects have been observed. However, physicians should instruct patients to report any unusual local side effects to the prescriber.

#### **Drug Interactions:**

Chi-Myst includes a chitin derivative, which is produced from shrimp shells. While it is unlikely to affect those suffering from shrimp or shellfish allergies, patients with allergies to shrimp or other shellfish should ask their physician before using Chi-Myst.

#### **Storage/Handling:**

Chi-Myst should be stored in a room-temperature environment (between 65F and 79F), and not exposed to direct sunlight for long periods of time.

#### **Inactive Ingredients:**

glycerin, a proprietary glucosamine polymer, lactic acid, sodium hydroxide

## **CHI-MYST SYNERGY TOPICAL**

chitosan ketorolac bupivacaine lidocaine suspension spray, metered

**Product Information**

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:70486-030
<b>Route of Administration</b>	TOPICAL		

**Active Ingredient/Active Moiety**

<b>Ingredient Name</b>	<b>Basis of Strength</b>	<b>Strength</b>
<b>BUPIVACAINE HYDROCHLORIDE</b> (UNII: 7TQO7W3VT8) (BUPIVACAINE - UNII:Y8335394RO)	BUPIVACAINE HYDROCHLORIDE ANHYDROUS	0.09 g in 30 mL
<b>KETOROLAC TROMETHAMINE</b> (UNII: 4EVE5946BQ) (KETOROLAC - UNII:YZI5105V0L)	KETOROLAC	0.45 g in 30 mL
<b>CHITOSAN LOW MOLECULAR WEIGHT (20-200 MPA.S)</b> (UNII: SBD1A2I75N) (CHITOSAN LOW MOLECULAR WEIGHT (20-200 MPA.S) - UNII:SBD1A2I75N)	CHITOSAN LOW MOLECULAR WEIGHT (20-200 MPA.S)	0.03 g in 30 mL
<b>LIDOCAINE HYDROCHLORIDE</b> (UNII: V13007Z41A) (LIDOCAINE - UNII:98PI200987)	LIDOCAINE HYDROCHLORIDE	1.5 g in 30 mL

**Inactive Ingredients**

<b>Ingredient Name</b>	<b>Strength</b>
<b>GLYCERIN</b> (UNII: PDC6A3C0OX)	0.3 mL in 30 mL
<b>WATER</b> (UNII: 059QF0KO0R)	30 mL in 30 mL
<b>LACTIC ACID LACTATE, DL-</b> (UNII: N37QW3EK1L)	0.042 mL in 30 mL
<b>SODIUM HYDROXIDE</b> (UNII: 55X04QC32I)	0.01950 g in 30 mL

**Packaging**

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:70486-030-00	30 mL in 1 BOTTLE, SPRAY; Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)	06/01/2016	

**Marketing Information**

<b>Marketing Category</b>	<b>Application Number or Monograph Citation</b>	<b>Marketing Start Date</b>	<b>Marketing End Date</b>
unapproved drug other		06/01/2016	

**Labeler** - Prescription Care LLC (080059076)**Registrant** - Prescription Care LLC (080059076)**Establishment**

<b>Name</b>	<b>Address</b>	<b>ID/FEI</b>	<b>Business Operations</b>
Prescription Care LLC		080059076	manufacture(70486-030)